Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Vasoactive drugs for the treatment of hepatorenal syndrome type 1

The latest issue of the Alimentary Pharmacology & Therapeutics re-evaluated efficacy and safety of pharmacological treatments for hepatorenal syndrome type 1.

News image

Hepatorenal syndrome type 1 is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis.
 
Characterized by intense renal arterial vasoconstriction, it carries a very poor prognosis. 

There is a significant unmet need for a widely approved, safe and effective pharmacological treatment.

Dr Fiona Gifford and colleagues from the United Kingdom re-evaluated efficacy and safety of pharmacological treatments for hepatorenal syndrome type 1, in the light of recently published randomized controlled trials.

MEDLINE (OvidSP), EMBASE, PubMed and Cochrane registers were searched for randomized controlled trials reporting efficacy and adverse events related to pharmacological treatment of hepatorenal syndrome type 1. 

Treatment with terlipressin and albumin led to hepatorenal syndrome type 1 reversal more frequently
Alimentary Pharmacology & Therapeutics
The team's search terms included: ‘hepatorenal syndrome’, ‘terlipressin’, ‘noradrenaline’, ‘octreotide’, ‘midodrine’, ‘vasopressin’, ‘dopamine’, ‘albumin’, and synonyms. 

Comparison of vasoactive drugs vs. placebo/no treatment, and 2 active drugs were included. 

The research team performed meta-analysis for hepatorenal syndrome type 1 reversal, creatinine improvement, mortality and adverse events.

The team included 12 randomized controlled trials enrolling 700 hepatorenal syndrome type 1 patients. 

Treatment with terlipressin and albumin led to hepatorenal syndrome type 1 reversal more frequently than albumin alone or placebo. 

The team of doctors observed that noradrenaline was effective in reversing hepatorenal syndrome type 1, but trials were small and nonblinded. 

Overall, the researchers observed that mortality benefit with terlipressin, but sensitivity analysis including only trials with low risk of selection bias weakened this relationship. 

Notably, there was a signifi cant risk of adverse events with terlipressin therapy.

Dr Gifford's team concludes, "Terlipressin treatment is superior to placebo for achieving hepatorenal syndrome type 1 reversal, but mortality benefit is less clear."

"Terlipressin is associated with significant adverse events, but infusion regimens may be better tolerated."

"There is continued need for safe and effective treatment options for hepatorenal syndrome."

Aliment Pharmacol Ther 2017: 45(5): 593–603
13 February 2017

Go to top of page Email this page Email this page to a colleague

 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 23 October 2017 
Irradiated rectal cancer and chemoradiotherapy
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Current management of chylous ascites
 18 October 2017 
Hep E seroprevalence and hemodialysis
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 18 October 2017 
Predicting recurrence after curative rectal cancer surgery
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Global recurrence rate of H. pylori
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 27 September 2017 
Function of trypsin-3 in IBS
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us